Sanofi has completed its acquisition of Dynavax Technologies Corporation, further strengthening its position in the global adult vaccines market. The deal brings Dynavax’s commercial hepatitis B vaccine HEPLISAV-B, along with a shingles vaccine candidate and additional pipeline assets, under Sanofi’s portfolio.

HEPLISAV-B, currently marketed in the United States, is differentiated by its two-dose regimen administered over one month, offering a shorter vaccination schedule compared to traditional hepatitis B vaccines. The acquisition also includes Dynavax’s investigational shingles vaccine candidate (Z-1018), currently in phase I/II clinical development, as well as other early-stage vaccine programmes.

The transaction enhances Sanofi’s adult immunisation strategy by combining Dynavax’s vaccine innovations with Sanofi’s global commercial infrastructure, development expertise and large-scale manufacturing capabilities.

Sanofi’s tender offer to acquire all outstanding shares of Dynavax common stock expired at 11:59 p.m. EST on February 9, 2026. All required conditions of the offer were satisfied and on February 10, 2026, Sanofi accepted and will promptly pay for all validly tendered shares.

Following the successful tender offer, Sanofi completed the acquisition through the merger of a wholly owned subsidiary into Dynavax under Section 251(h) of Delaware law. Dynavax will continue as the surviving entity and operate as an indirect, wholly owned subsidiary of Sanofi. Shareholders received USD 15.50 per share in cash, without interest and subject to applicable withholding taxes. As of February 10, 2026, Dynavax’s common stock ceased trading on the NASDAQ Global Select Market.

Sanofi, an R&D-driven and AI-powered biopharmaceutical company, continues to expand its vaccine and immunology portfolio as part of its strategy to deliver innovative therapies and preventive solutions to patients worldwide.